AK104+Axitinib
Phase 1Small molecule
AK104+Axitinib is one of 57 small molecule programs targeting Melanoma. It is currently in Phase 1.
2
Indications
1
Total Trials
1
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiPhase 3
Incomplete Freund's Adjuvant
EEastern Cooperative Oncology Group
Phase 3
Intismeran Autogene
Merck & Co.Phase 3
Actimmune
HHorizon Therapeutics Ireland DAC
Phase 3
Masitinib
AAB Science
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
BCD-217
BBiocad
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Naporafenib
EErasca, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Melanoma1 trial
A Phase Ib, Open, Mono-center, Dose-reduction Tolerability Study of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
Enrolling by invitation·PPeking University Cancer Hospital & Institute·Phase 1·NCT06424626·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK104+Axitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details